ExLibris header image
SFX Logo
Title: CRISPR off-targets: a reassessment
Source:

Nature Methods [1548-7091] yr:2018


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Fellmann, C. "Cornerstones of CRISPR-Cas in drug discovery and therapy." Nature reviews. Drug discovery 16.2 (2016): 89-100. Link to SFX for this item
2. Hsu, P. "Development and Applications of CRISPR-Cas9 for Genome Engineering." Cell 157.6 (2014): 1262-1278. Link to SFX for this item
3. Shalem, O. "Genome-scale CRISPR-Cas9 knockout screening in human cells." Science 343.6166 (2014): 84-87. Link to SFX for this item
4. Li, T. "PreDNA: accurate prediction of DNA-binding sites in proteins by integrating sequence and geometric structure information." Bioinformatics 29.6 (2013): 678-685. Link to Full Text for this item Link to SFX for this item
5. Lee, B. "Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression." Nature biotechnology 30.12 (2012): 1244-1248. Link to SFX for this item
6. Broxterman, H. "Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations." Drug resistance updates 8.4 (2005): 183-197. Link to SFX for this item
7. Wang, T. "Genetic Screens in Human Cells Using the CRISPR/Cas9 System." Science 343.6166 (2013): 1-8. Link to SFX for this item
8. Cong, David e. "Multiplex Genome Engineering Using CRISPR/Cas Systems." Science 339.6121 (2013): 819-823. Link to SFX for this item
9. Doudna, Jennifer A. "The new frontier of genome engineering with CRISPR-Cas9." Science 346.6213 (2014): 96-1258096. Link to SFX for this item
10. Sander, Jeffry D. "CRISPR-Cas systems for editing, regulating and targeting genomes." Nature biotechnology 32.4 (2014): 347-355. Link to SFX for this item
11. Ran, Patrick A. "Genome engineering using the CRISPR-Cas9 system." Nature protocols 8.11 (2013): 2281-2308. Link to SFX for this item
12. Sanjana, Neville E. "Improved vectors and genome-wide libraries for CRISPR screening." Nature Methods 11.8 (2014): 783-784. Link to SFX for this item
13. Bai, Y. "Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9." Cell stem cell 13.6 (2013): 659-662. Link to SFX for this item
14. Jain, S. "Footprinting protein-DNA complexes using the hydroxyl radical.(PROTOCOL)." Nature protocols 3.6 (2008): 1092-. Link to Full Text for this item Link to SFX for this item
15. Garate, Z. "New Frontier in Regenerative Medicine : Site-Specific Gene Correction in Patient-Specific Induced Pluripotent Stem Cells." Human gene therapy 24.6 (2013): 571-583. Link to SFX for this item
16. Shetty, Ranjit S. "Specific correction of a splice defect in brain by nutritional supplementation." Human molecular genetics 20.21 (2011): 4093-4101. Link to SFX for this item
17. Antczak, C. "Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase." Bioorganic and medicinal chemistry letters (2011). Link to SFX for this item
18. Wickstrom, M. "Aminopeptidase N (CD13) as a target for cancer chemotherapy." Cancer science 102.3 (2011): 501-508. Link to Full Text for this item Link to SFX for this item
19. Murata, M. "Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery." Pharmacology & therapeutics 126.2 (2010): 109-118. Link to SFX for this item
20. Lee, G. "Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs." Nature 461.7262 (2009): 402-406. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.